At ACR Convergence 2023, panelists presented information concerning several policy issues that affect rheumatologists & their patients, including abortion access & the WHO’s Essential Medicine List.
Rheum in the Court, Law in the Clinic: Health Policy in Global Rheumatology
At ACR Convergence 2023, panelists presented information concerning several policy issues that affect rheumatologists & their patients, including abortion access & the WHO’s Essential Medicine List.
Pediatric Clinical Year in Review: 2023
SAN DIEGO—Too many excellent pediatric rheumatology studies to squeeze into one talk? What a good problem to have. Dr. Ardoin first highlighted baricitinib in juvenile idiopathic arthritis.
Life with Arthritis: Kaleb Michaud, PhD, Shares His Story
SAN DIEGO—“I’m going to get personal,” said Kaleb Michaud, PhD, in the ARP Distinguished Lecture at ACR Convergence 2023. When he was 3 years old, the young Kaleb was diagnosed him with juvenile rheumatoid arthritis (JRA).
Growing Up
SAN DIEGO—In the pre-ACR Convergence 2023 Review Course, Rebecca Sadun, MD, PhD, assistant professor in medicine and pediatrics, Duke University School of Medicine, Durham, N.C., focused on transitions from pediatric to adult rheumatology care for patients with juvenile idiopathic arthritis (JIA).
FDA Approves New Biosimilar for Adult & Pediatric Arthritis
This year, tocilizumab biosimilars have been approved to treat adult and pediatric patients with rheumatic disease, including rheumatoid arthritis, juvenile idiopathic arthritis and more, in both Europe and the U.S.
FDA Approves Ustekinumab for Children with PsA
After examining study data from pediatric patients with both psoriasis and psoriatic arthritis (PsA), the FDA approved ustekinumab as a treatment for patients aged 6–17 years old with PsA.
Changing Treatment Patterns for Patients with JIA
A study from Glerup et al. demonstrated that many patients with juvenile idiopathic arthritis achieved drug-free remission over 18 years of follow-up and that remission rates remained stable between years 8 and 18 of the study period.
Belimumab Promising for Children with Lupus Nephritis
Belimumab is now FDA approved to treat children aged 5 years and older with active lupus nephritis, providing treatment options for pediatric patients at risk of developing renal damage.
Baricitinib Promising for Juvenile Idiopathic Arthritis
In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.
- 1
- 2
- 3
- …
- 11
- Next Page »